Paper Details

  1. Home
  2. Paper Details

Safety and Efficacy of Vadadustat for Anemia in Patients Undergoing Dialysis.

Author: AgarwalRajiv, AswadAhmad, AwadAhmed, BacciMarcelo R, BlockGeoffrey A, ChertowGlenn M, EckardtKai-Uwe, FaragYoussef M K, FishbaneSteven, HubertHarold, JardineAlan, KhawajaZeeshan, KouryMark J, LewisEldrin F, LuoWenli, MaroniBradley J, MatsushitaKunihiro, McCulloughPeter A, ParfreyPatrick S, PergolaPablo, SarnakMark J, SpinowitzBruce, TumlinJames, VargoDennis L, WaltersKimberly A, WinkelmayerWolfgang C, WittesJanet, ZwiechRafal

Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Equivalence TrialA clinical trial designed to show that a new treatment is equivalent in efficacy/safety to an existing treatment.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

Vadadustat was compared to darbepoetin alfa in two phase 3 trials for the treatment of anemia in patients with dialysis-dependent chronic kidney disease (DD-CKD). Vadadustat was noninferior to darbepoetin alfa with respect to cardiovascular safety and correction and maintenance of hemoglobin concentrations.
Paper Details　
Original Abstract of the Article :
BACKGROUND: Vadadustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor, a class of compounds that stimulate endogenous erythropoietin production. METHODS: We conducted two randomized, open-label, noninferiority phase 3 trials to evaluate the safety and efficacy of vadadustat, as co...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1056/NEJMoa2025956

データ提供：米国国立医学図書館（NLM）

A New Hope for Anemia in Dialysis Patients: Vadadustat

Imagine a desert where the sands are constantly shifting, making it difficult for life to thrive. That's what anemia is like, a condition where the body lacks enough red blood cells to carry oxygen throughout the body. This study explores the potential of vadadustat, a new oral medication, to treat anemia in patients undergoing dialysis. They compared vadadustat to darbepoetin alfa, a commonly used treatment, and found that vadadustat was just as effective in controlling anemia while also being safe for the heart.

A New Oasis in the Desert of Anemia

The researchers are like explorers who have discovered a new oasis in the desert of anemia treatment. Their research reveals that vadadustat is a promising new option for patients with anemia who are on dialysis. They found that vadadustat was just as effective as darbepoetin alfa in raising hemoglobin levels, but it was also associated with a lower risk of cardiovascular complications.

A Balancing Act for Dialysis Patients

For people with anemia who are on dialysis, finding the right treatment is a delicate balancing act. This research provides a glimmer of hope with the discovery of vadadustat. This new medication appears to be an effective and safe option for managing anemia while minimizing the risk of cardiovascular complications.

Dr.Camel's Conclusion

This study offers a beacon of hope in the desert of anemia treatment for dialysis patients. Vadadustat emerges as a promising new option that can help to improve patients' lives while also protecting their heart health. The research serves as a reminder that even in the face of seemingly insurmountable challenges, new solutions can emerge.

Date :
  1. Date Completed 2021-05-05
  2. Date Revised 2021-10-14
Further Info :

Pubmed ID

33913638

DOI: Digital Object Identifier

10.1056/NEJMoa2025956

Related Literature

Article Analysis
・Effects of vadadustat
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.